WA
CNCE

Winfield Associates’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History

Winfield Associates’s Portfolio CNCE Stock Details CNCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-1,000
Closed -$13K – 309
2014
Q3 		$13K Hold
1,000
– – 0.01% 227
2014
Q2 		$10K Hold
1,000
– – 0.01% 251
2014
Q1 		$13K Buy
+1,000
New +$14.1K 0.01% 229

Other funds holding CNCE

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
SAM
Senzar Asset Management New York $34.7M AUM 0.56% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WSA
Wall Street Associates Lajolla, California $151M AUM 30.3% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return

Winfield Associates's CNCE Position: Q4 2014 in Review

Winfield Associates sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q4 2014, closing a stake of 1,000 shares — an estimated $13K sold.

Winfield Associates first reported a position in CNCE in Q1 2014 and held it in 3 quarters. The position peaked at $13K in Q3 2014. 54 funds tracked by Wall St. Rank hold CNCE as of Q4 2014.

  • Winfield Associates reported no remaining Concert Pharmaceuticals, Inc. position as of Q4 2014 after selling out during the quarter.
  • Winfield Associates sold 1,000 Concert Pharmaceuticals, Inc. shares in Q4 2014, an estimated $13K.
  • Winfield Associates first reported a position in Concert Pharmaceuticals, Inc. in Q1 2014 and held it in 3 quarters.
  • Winfield Associates's Concert Pharmaceuticals, Inc. position peaked at $13K in Q3 2014.
  • 54 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q4 2014.

Based on Winfield Associates's 13F filing for Q4 2014, filed 28 Jan 2015.